Biopharma Funding Drops 20% in 2025 as China Deals Surge to Record Levels
Global biopharma funding fell 20% in 2025, marking the first post-pandemic decline, while IPO proceeds dropped to a 10-year low, even as mega-deals valued above $2 billion surged dramatically, particularly involving Chinese biotechs.
Key Points
- Biopharma funding fell 20% in 2025, the first post-pandemic decline
- IPO proceeds dropped to the lowest level in 10 years
- Mega-deals ($2B+) surged to 68 in 2025 from 27 in 2024, totaling $360B
- Chinese biotechs accounted for 10 mega-deals worth over $2B each
Full Details
According to IQVIA's annual report, biopharma funding experienced a significant 20% decline in 2025, reversing the post-pandemic recovery trend. The IPO haul dropped to its lowest level in the past decade, creating challenges for biotech companies seeking public market capital. Despite the overall funding contraction, there was a dramatic surge in mega-deals, with 68 M&A, alliance, or licensing deals valued at more than $2 billion in 2025, up from just 27 the previous year. The total value of these large deals reached $360 billion compared to $102 billion in 2024. Ten of these mega-deals specifically involved Chinese biotechs, each valued at over $2 billion. Oncology remained the dominant therapeutic area, accounting for 25% of deal volume and 32% of total deal value, while small molecules continued to represent more than half of all deals, showing little change in modality mix over seven years.
Why It Matters
The divergence between declining overall funding and surging mega-deals suggests biopharma is consolidating around fewer but larger bets, with Chinese biotechs becoming increasingly attractive acquisition targets for global pharmaceutical companies.
Get stories like this delivered daily
AI-curated news, personalized to your interests. Zero noise.
Start 7-Day Free Trial →More in Technology & Startups
Israeli High-Tech Raises $3.1 Billion in Q1 2026, Up 34% Year-over-Year
Israeli tech companies raised approximately $3.1 billion across 98 funding rounds in Q1 2026, representing a 34% increase compared to the same period last year, with early-stage deals accounting for over $1.3 billion.
SpaceX Transporter-16 Mission Carries 119 Payloads to Orbit
SpaceX's Transporter-16 mission successfully launched 119 payloads to orbit from Vandenberg Space Force Base, marking the company's first rideshare mission of 2026 and featuring advanced communications and in-space technology demonstrations.
Fintech Funding Roundup: KAST, Silverflow, and Worth Secure Major Rounds
Multiple fintech companies secured significant funding in March 2026, with KAST raising $80 million for stablecoin payments, Silverflow closing a $40 million Series B, and Worth raising $30 million in Series A funding.
Defense Technology Startup Shield AI Valued at $12.7 Billion in $2 Billion Funding Round
Shield AI, a defense technology startup, is raising $2 billion in a new funding round that values the company at $12.7 billion, as it looks to expand its operations and technology development in the defense sector.